Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment ...

For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

The findings, which were presented at the 50th Annual Oncology Nursing Society Congress, showed that at a median follow-up of ...

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the ...

The MindCap mobile app is likely feasible as an assessment for cognitive function of cancer survivors, although further data ...

Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with ...

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.

Social determinants of health like transportation and financial increased the occurrence of psychoneurological symptoms in breast cancer survivors.

Sessions addressing supportive care needs for patients with cancer on early phase clinical trials appeared feasible and ...

Using risk assessment and nurse education in the High ED/Admission Risk Therapy (HEART) protocol reduced ED visits by 18% ...

Panelists discuss how advanced practice providers (APPs) implement effective monitoring strategies for patients with chronic myeloid leukemia (CML), including regular check-ins after starting new ...